Updated:
Entrée Capital
Entrée Capital is a venture capital based in Tel Aviv, managing $1.5B; the Altss profile covers its classification, headquarters, registration, AUM band, and...
Entrée Capital
Entrée Capital are a team of ex-serial founders managing $1.5bn across a number of funds, with offices in Tel Aviv, London, and New York.
General information
Firm type
Venture Capital
AUM
$1.5B (per firm website)
Location
Region
Middle East
Country
Israel
City
Tel Aviv
Corporate office
Tel Aviv, Israel
Additional offices
London, United Kingdom · New York, United States
Principals
Aviad (Avi) Eyal
Co-Founder and Managing Partner
Ran Achituv
General Partner
Eran Bielski
General Partner
Yoni Osherov
General Partner
Saul Levin
Partner
Sector focus
Frequently asked questions
Who makes investment decisions at Entrée Capital?
Aviad Eyal leads the partnership as co-founder and Managing Partner. General Partners Ran Achituv, Eran Bielski, and Yoni Osherov complete the senior investment committee. Tomer Niv directs the crypto practice, while Entrée Bio is led separately by Yael Gruenbaum-Cohen with advisory from John Maraganore (per firm website).
How does Entrée Capital source its deals?
Entrée's partners are former serial founders and operators. Avi Eyal provides first institutional capital to several companies, giving rise to a repeat-founder network. The firm also runs SigmaLabs, a non-profit accelerator, which serves as a top-of-funnel for Israeli seed-stage deal flow. Its in-house data team, led by a VP of Data, systematically tracks the early-stage ecosystem.
Does Entrée Capital do follow-on investments in portfolio companies?
Yes. The firm invests from Seed to Growth and reserves capital for follow-on rounds. Its March 2025 $300M fundraise was explicitly structured to back companies across stages, signaling continued appetite for multi-stage support (per firm website, March 2025).
What is Entrée Capital's geographic focus?
The firm operates from Tel Aviv, London, and New York. Its portfolio is concentrated in Israel while extending into the United States (Stripe, PillPack, Coupang) and Europe (Deliveroo). The London office anchors its European deal flow.
How is Entrée Capital's life science investing structured?
Entrée runs a dedicated life-science vehicle called Entrée Bio, co-founded by Yael Gruenbaum-Cohen, a former aMoon Partner with a DMD and Ph.D. in molecular genetics. The advisory bench includes John Maraganore, the founding CEO of Alnylam Pharmaceuticals, giving the firm specialized biotech expertise separate from its core tech venture funds.
What is Entrée Capital's relationship with monday.com?
Avi Eyal provided the first capital to monday.com and led the firm's investment. The company went public on Nasdaq in 2021. Yoni Osherov, who joined Entrée as a General Partner in 2025, was the Chief Revenue Officer at monday.com and helped scale it from $10M to over $1B in ARR (per firm website).
Does Entrée Capital manage a dedicated crypto fund?
The firm does not publicly market a standalone crypto fund, but it has a dedicated crypto strategy run by Tomer Niv, a former eToro executive. The March 2025 $300M fundraise explicitly includes crypto as a core mandate pillar, signaling a formal allocation alongside AI and deep-tech.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: